OPTION CARE HEALTH INC (OPCH)
Health Care · home infusion services · NASDAQ
Option Care Health is a national leader in home and alternate site infusion services, providing essential, complex clinical care to patients outside of hospital settings.
What OPTION CARE HEALTH INC does
Option Care Health is a leading provider of home and alternate site infusion services in the United States. The company provides clinical care and pharmaceutical therapy management for patients with chronic and complex conditions, delivering treatments directly to their homes or through infusion centers.
Themes: home infusion services, specialty pharmacy, clinical care services, chronic disease management
Fundamentals
- Price$31.05 as of 2026-10-08 close
- Market cap$4.9B as of 2026-04-28 (share count; price 2026-10-08)
- 1-year return+14.2% 2025-10-08 close $27.19 → 2026-10-08 close $31.05
- P/E23.49 as of 2026-10-08
- Net margin+3.7% FY2025, SEC XBRL
- Gross margin+19.3% FY2025, SEC XBRL
- ROE+15.7% FY2025, SEC XBRL
- Debt / equity0.92 as of 2026-09-02
- Revenue growth (YoY)+6.0% as of 2026-09-02
- Revenue CAGR (3y)+13.4% SEC XBRL
- Beta0.34 as of 2026-09-02
- Last reported earnings2026-07-29 SEC EDGAR Form 8-K (Item 2.02)
How OPCH compares in its sector
- price-to-earnings ratiomiddle range 185 covered Health Care peers, as of 2026-10-08
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-02
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-02
- gross marginbottom 10% 189 covered Health Care peers, as of 2026-09-02
- return on equitytop 25% 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
OPCH is not currently in any published Top 10 list. Its scores are below.
Top 10 score
51.6 #640 of 1,379 scored · #78 of 151 in Health Care
Trend 61st (a trend forming but not yet strong (ADX below 25)) and valuation 58th (price to earnings 23.5, price to book 3.6); weakest is financial health (31st, free cash flow margin 3.8%, debt to equity 0.9).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
How OPTION CARE HEALTH INC looks technically
OPTION CARE HEALTH INC (OPCH) is trading 16.5% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 111 trading days ago — a "death cross", a bearish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 24 (a reading of 25+ marks a strong trend). Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 84, in overbought territory (above 70). MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive). It just made a new 20-day high, its first since 2026-03-03, pushing above its recent trading range. It is 15.6% below its highest point of the past year. Trading volume is running unusually high — about 2.1× its 30-day average, a sign of heightened interest.
Trend
9
| Distance from the 200-day | it is trading 16.5% above its 200-day average, the long-term trend line — a longer-term uptrend | +16.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $24.06 | $24.06 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $26.66 | $26.66 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 22.29. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 111 trading days ago — a "death cross", a bearish long-term signal | 111 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 16.5% above | +16.5% |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 24 (a reading of 25+ marks a strong trend) | 24.0 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 84, in overbought territory (above 70) | 83.8 |
|---|---|---|
| Position in its 14-day range | it is trading right at the top of its 14-day range ($22.29 to $31.11) — its "stochastic" reading is 99 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 99.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive) | 3 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $36.80 | $36.80 |
|---|---|---|
| From the 52-week high | it is 15.6% below its 52-week high (its highest price of the past year) | -15.6% |
| Above the 52-week low | it is 72.4% above its 52-week low (its lowest price of the past year) | +72.4% |
| Below the 52-week high | it is 15.6% below its highest point of the past year | 15.6% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-03-03, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, its first since 2026-03-03, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $70.48 (set on 2013-07-09) | $70.48 |
| Given back of the 52-week move | over the past year its closes ranged ($19.52 to $36.59), and it has recovered well over two thirds of its fall from last year’s high — 68% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $30.07 to $30.62. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 67.5% |
| From the all-time high | it is 55.9% below its all-time high | -55.9% |
| Nearest price level | it is trading 1.0% above a support level at $30.73 — a price it turned at 8 times since 2025-02-03, most recently on 2026-03-19. Since 2024-10-08 it has 10 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.0% |
| All-time low | its lowest closing price on record is $3.92 (set on 2016-12-29) | $3.92 |
| Above the all-time low | it is 692.1% above its all-time low | +692.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 88% of the past ~6 months) | 88th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.01 between its high and its low — about 3.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.01 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $19.01 and $30.12 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $19.01 – $24.57 – $30.12 |
| Typical daily range (% of price) | its price moves about 3.3% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.3% |
| Stretch from the 200-day average | it is trading 4.3 daily ranges above its 200-day average price (16.5% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.3 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is running unusually high — about 2.1× its 30-day average, a sign of heightened interest | 2.06× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.1% |
|---|---|---|
| Open gap | it gapped 32.8% above the previous close 2 sessions ago and has not traded back through the level it left behind at 23.37 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +32.8% |
| Gap filled | a 4.0% gap down opened on 2026-07-30 has been "filled" 49 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 49 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 6 sessions in a row, a +38.06% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 6 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 29.8 percentage points (the stock gained 30.8% while the market gained 1.0%) | +29.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 40.8 percentage points (the stock gained 44.6% while the market gained 3.8%) | +40.8% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 5.5 percentage points (the stock gained 12.0% while the market gained 17.5%) | -5.5% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 0.8 percentage points (the stock gained 14.2% while the market gained 15.0%) | -0.8% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, its RSI momentum gauge is overbought (a stretched reading), lagging the market over 6 months, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 32% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 2.2% of the share price. | +32.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 19% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $26.10 — a volume-weighted average of daily closes over 189 sessions, not a true tick-by-tick VWAP. | +19.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 15% above the average price paid since it last reported on 2026-07-29 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $27.10 — a volume-weighted average of daily closes over 51 sessions, not a true tick-by-tick VWAP. | +14.6% |
Price levels it has turned at before
OPCH last closed at $31.05 on 2026-10-08. Since 2024-10-08 it has turned at 10 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $30.73 | Support | 1.0% below the last close | turned there 8 times · 2025-02-03 to 2026-03-19 |
| $31.56 | Resistance | 1.6% above the last close | turned there four times · 2024-10-18 to 2025-11-28 |
| $32.36 | Resistance | 4.2% above the last close | turned there twice · 2025-03-13 to 2025-06-30 |
| $29.54 | Support | 4.9% below the last close | turned there six times · 2025-04-29 to 2026-04-09 |
| $28.74 | Support | 7.4% below the last close | turned there 7 times · 2025-07-22 to 2026-03-09 |
| $33.51 | Resistance | 7.9% above the last close | turned there six times · 2025-04-29 to 2026-01-30 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $22.29.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 3 trading days, since 2026-10-06.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Overbought (14-day RSI above 70) · Unusually heavy trading volume · Broke out to a new 20-day high · Broke out to a new 20-day high on heavy volume | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$28.58 range $23.00 – $39.00; median $28.00
Analyst estimates, as of 2026-10-04. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for OPCH
- Consensus EPS estimate$0.4871 next reporting period, as of 2026-10-04
- Estimate change, 30 days$0.00 (0.0%) from $0.4871, on 2026-08-30, 35-day window
- Readings revised upward0% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on reimbursement from third-party payers and government health programs.","Potential for disruptions in pharmaceutical supply chains and drug shortages.","Complexity of regulatory compliance and evolving healthcare policies."]
What changed in the latest 10-Q
AI-assisted comparison of OPCH's 10-Q filed 2026-04-30 against the prior one filed 2025-10-30.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing specifies company has 87 full service pharmacies (73 with ambulatory infusion suites) and 111 stand-alone ambulatory infusion suites (28 with advanced practitioner capabilities), versus older filing's generic reference to 192 locations
- Newer filing adds narrative about national footprint enabling collaboration with health systems and national payers, and emphasizes patient-centered approach
- Newer filing references Form 10-K for year ended December 31, 2025 (versus older filing's December 31, 2024)
- Newer filing presents financial results for three months ended March 31, 2026 and 2025 (versus older filing's three and nine months ended September 30, 2025 and 2024)
- Newer filing's Interest Expense, Net description adds 'and fee payments' to the list of components
- Removed:
- Older filing describes company as contracting with managed care organizations, third-party payers, hospitals, physicians and other referral sources to provide pharmaceuticals and complex compounded solutions for intravenous delivery in patients' homes or other nonhospital settings (language removed in newer filing)
- Older filing states 'The Company operates in one reporting segment, infusion services' (statement removed in newer filing)
- Older filing references Form 10-K for year ended December 31, 2024 (replaced with 2025 reference in newer filing)
- Reworded:
- Older filing states company 'provides' infusion therapy; newer filing states company 'provide' infusion therapy
- Older filing uses 'healthcare' (one word) in one instance; newer filing uses 'health care' (two words) in Business Overview
- Older filing describes 'Other (expense) income' with parenthetical on expense; newer filing reverses to 'Other income (expense)' with parenthetical on expense
- Newer filing's financial table shows different periods (Q1 2026 vs Q1 2025) compared to older filing (Q3 2025 vs Q3 2024, and nine-month comparisons)
- Notes:
- The two filings cover different fiscal periods (March 31, 2026 vs September 30, 2025), making direct line-item comparison of financial results not directly comparable
- Newer filing text appears truncated ('The follo' at end), limiting assessment of complete narrative changes in results discussion
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 180 days · read to 2026-10-044 buys ($2M) · 0 sells — 4 buying insiders
Cluster buying: 4 different insiders reported open-market purchases (SEC code P) of OPCH within a 30-day window between 2026-05-04 and 2026-05-07. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Most recent open-market transaction: 2026-05-07. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about OPCH's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 4 matched disclosures for OPCH from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding OPCH as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 35,533,692
- Reported value $745,141,524
reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 3 increased, 1 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about OPCH's institutional holders → See what each manager we track holds →
Short interest (FINRA)
OPCH had 12,098,760 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
OPCH had 7.70% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.5 days to cover at the same settlement.
- Reported short interest (shares) 12,098,760
- Short interest (% of shares outstanding) 7.70%
- Prior settlement (shares) 12,666,901
- Reported change -4.49%
- Days to cover (reported) 7.5
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- CVS Health (CVS)
- Walgreens Boots Alliance (WBA)
- UnitedHealth Group (UNH)
- Option Care Health's competitive landscape also includes regional home infusion providers and hospital-based programs.
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare OPCH vs…
OPTION CARE HEALTH INC is found in…
Frequently asked questions
What does OPTION CARE HEALTH INC (OPCH) do?
Option Care Health is a leading provider of home and alternate site infusion services in the United States. The company provides clinical care and pharmaceutical therapy management for patients with chronic and complex conditions, delivering treatments directly to their homes or through infusion centers.
What sector is OPTION CARE HEALTH INC (OPCH) in?
OPTION CARE HEALTH INC (OPCH) is classified in the Health Care sector. Its industry is home infusion services. It trades on NASDAQ.
Who are OPTION CARE HEALTH INC's (OPCH) competitors?
Notable peers of OPTION CARE HEALTH INC (OPCH) include CVS Health, Walgreens Boots Alliance, UnitedHealth Group and Option Care Health's competitive landscape also includes regional home infusion providers and hospital-based programs.. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in OPCH?
Yes — we hold 4 matched STOCK Act disclosures for OPCH from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is OPTION CARE HEALTH INC (OPCH) overbought or oversold right now?
OPTION CARE HEALTH INC (OPCH) is currently in overbought territory (its 14-day RSI is 84, above 70) (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on OPCH come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.